Ozempic increases risk of debilitating eye condition: studies

Original Article ↗ Hacker News Discussion ↗

New observational studies from Denmark suggest that semaglutide (sold as Ozempic and related drugs) may roughly double the risk of a rare eye condition, non‑arteritic anterior ischemic optic neuropathy (NAION), which can cause sudden, permanent vision loss. Commenters note that the absolute risk remains very low—on the order of 1–2 extra cases per 10,000 patients per year—and weigh this against the substantial benefits of GLP‑1 drugs for type 2 diabetes, obesity, and potentially addiction and inflammation. Much of the debate centers on interpreting relative vs absolute risk, the limits of observational data, and the ethical and practical tradeoffs of using powerful long‑term medications for weight loss and metabolic disease.

NAION risk and how big it is

  • Discussion centers on semaglutide (Ozempic/Rybelsus, possibly Wegovy) and a rare eye condition: non‑arteritic anterior ischemic optic neuropathy (NAION), which causes sudden, usually painless vision loss in one eye.
  • Studies report roughly a doubling of NAION risk in type 2 diabetics on once‑weekly semaglutide.
  • Absolute risk remains low: around 0.2 cases per 1,000 person‑years, with ~1.5–2.5 additional cases per 10,000 treated people per year.
  • Some argue that “risk doubling” sounds alarming without base rates; others note that even rare doubled risks merit attention if mechanisms are unknown.

Causality, study design, and data

  • Both Danish studies are observational cohort designs; commenters stress they cannot prove causation.
  • One view: “correlation is not causation” is overused and can be weaponized to dismiss legitimate signals; still, more research is needed, especially given NAION’s rarity.
  • Concerns raised about confounding: semaglutide users may be sicker on average.
  • One commenter notes NAION incidence peaks align more with COVID timing than with semaglutide uptake, suggesting possible alternative explanations (speculative within thread).

Context: diabetes, obesity, and relative risk

  • Multiple comments emphasize that untreated type 2 diabetes and obesity already carry high risks (including blindness, cardiovascular disease, kidney damage).
  • Consensus in the thread: any added NAION risk from semaglutide is likely much smaller than the overall health risks from diabetes/obesity.

Use for weight loss vs diabetes

  • Studies discussed focus on type 2 diabetics; impact on non‑diabetic weight‑loss users is labeled “unclear.”
  • Some argue current media coverage should draw a clearer distinction, given explosive off‑label/weight‑loss use.

Side effects, benefits, and long‑term uncertainty

  • GLP‑1 agonists are said to have relatively low intrinsic hypoglycemia risk unless combined with other diabetic drugs.
  • Reported benefits go beyond weight loss: reduced cravings/addictive behaviors, improved sleep and functioning, and possible anti‑inflammatory and neuroprotective effects (all based on anecdotes and early studies cited in the thread).
  • Others warn of GI and other side effects, unknown decades‑long safety, and the likelihood of weight regain after stopping.

Ethical and cultural debate

  • Strong clash between:
    • A camp viewing GLP‑1 use for obesity as an acceptable, even transformative medical tool.
    • A camp framing obesity mainly as personal responsibility and seeing drugs as “easy way out” with “nature’s price.”
  • Counter‑arguments stress addiction‑like dynamics of overeating, biological variability, and the legitimacy of medical “shortcuts” when they improve health.